

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

---

THE GENERAL HOSPITAL  
CORPORATION and  
DANA-FARBER CANCER  
INSTITUTE, INC.,

Plaintiffs,

v.

ESOTERIX GENETIC  
LABORATORIES, LLC and  
LABORATORY CORPORATION  
OF AMERICA HOLDINGS,

Defendants.

---

C.A. No. 1:18-cv-11360-IT

**CORPORATE DISCLOSURE STATEMENT**

The plaintiff Dana-Farber Cancer Institute, Inc., by and through its undersigned counsel, submits this corporate disclosure statement pursuant to Fed. R. Civ. P. 7.1 identifying: 1) any parent corporation; and 2) any publicly held company that owns 10% or more of the party's stock.

The Dana-Farber Cancer Institute, Inc. has no parent corporation and no publicly held company owns 10% or more of Dana-Farber Cancer Institute, Inc.'s stock.

\* \* \* \* \*

Respectfully submitted,

DANA-FARBER  
CANCER INSTITUTE, INC.  
By its attorneys,

/s/ Carolyn A. Marcotte  
Douglas J. Nash (BBO# 633050)  
Carolyn A. Marcotte (BBO# 663616)  
Barclay Damon LLP  
One Financial Center, Suite 1701  
Boston, MA 02111  
(617) 274-2900  
dnash@barclaydamon.com  
cmarcotte@barclaydamon.com

Dated: July 24, 2018

**CERTIFICATE OF SERVICE**

I, Carolyn A. Marcotte, counsel for plaintiff Dana-Farber Cancer Institute, Inc. in the above-captioned action, certify that on July 24, 2018, this Corporate Disclosure Statement filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing and paper copies will be sent to the non-registered participants.

/s/ Carolyn A. Marcotte  
Carolyn A. Marcotte